<DOC>
	<DOCNO>NCT00004107</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate cancer cell deliver cancer-killing substance without harm normal cell . Peripheral stem cell transplantation may able replace immune cell destroy monoclonal antibody therapy use kill cancer cell . PURPOSE : Phase I/II trial study effectiveness radiolabeled monoclonal antibody therapy plus peripheral stem cell transplantation treat patient lymphoma Waldenstrom 's macroglobulinemia respond previous therapy .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation Treating Patients With Lymphoma Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose limit toxicity radioimmunotherapy use high dose yttrium Y 90 humanize anti-CD22 monoclonal antibody LL2 ( Y90 MOAB hLL2 ) follow autologous peripheral blood stem cell transplantation patient B cell lymphoma Waldenstrom 's macroglobulinemia . II . Determine organ tumor dosimetry comparison clinical measurement toxicity antitumor responses patient . III . Determine magnitude duration human anti-humanized LL2 antibody ( HAhLL2 ) anti-DOTA response patient . IV . Evaluate extent duration antitumor response regimen patient . OUTLINE : This dose escalation , multicenter study . Patients stratify accord prior treatment ( high dose chemotherapy transplantation v low dose chemotherapy radioimmunotherapy ( RAIT ) vs low dose chemotherapy without RAIT ) . Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily 5 day undergo harvest peripheral blood stem cell ( PBSC ) . If adequate number CD34+ cell harvest , autologous bone marrow may use . Patients undergo pretherapy image indium In 111 monoclonal antibody MN-14 ( In111-MN-14 ) IV day -7 . If least 1 tumor site target , patient receive high dose yttrium Y 90 humanize anti-CD22 monoclonal antibody LL2 ( Y90 MOAB hLL2 ) IV 50 minute day 0 . PBSC bone marrow reinfused approximately 7-14 day follow infusion Y90 MOAB hLL2 . Patients also receive G-CSF SC daily 3 day blood count recover . Cohorts 3-6 patient receive escalate dos Y90 MOAB hLL2 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow weekly 2 month , monthly 6 month , every 6 month 5 year . PROJECTED ACCRUAL : A total 12-24 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven B cell lymphoma one follow type : Any histologic grade nonHodgkin 's lymphoma Chronic lymphocytic leukemia CD22 positive acute lymphocytic leukemia Waldenstrom 's macroglobulinemia Must fail least 1 standard therapy Autologous peripheral blood stem cell ( PBSC ) bone marrow available Bone marrow involvement allow : Autologous bone marrow PBSC great 5 % tumor involvement available Radiation dose marrow great 3,000 cGy 6 patient safely treat dose level At least 1 confirmed site tumor target pretherapy indium In 111 monoclonal antibody MN14 image No brain metastasis PATIENT CHARACTERISTICS : Age : 18 80 Performance status : Karnofsky 70100 % ECOG 02 Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL AST alkaline phosphatase less 1.5 time upper limit normal ( ULN ) absence bone involvement Renal : Creatinine le 1.5 time ULN Cardiovascular : Ejection fraction least 50 % Pulmonary : DLCO least 60 % predict Forced vital capacity least 60 % predict Other : No severe anorexia , nausea , vomit No concurrent significant medical complication would preclude study participation Not pregnant Negative pregnancy test Fertile patient must use effective contraception 3 month study HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : No prior radioimmunotherapy AND high dose chemotherapy Chemotherapy : No prior high dose chemotherapy AND radioimmunotherapy At least 4 week since prior chemotherapy recover Endocrine therapy : At least 2 week since prior corticosteroid recover Radiotherapy : No prior radioimmunotherapy AND high dose chemotherapy At least 4 week since prior radiotherapy index lesion No prior radiotherapy great 25 % critical organ ( e.g. , lung , liver , kidney ) No prior total body irradiation Surgery : At least 4 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>B-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>